Sugi Predict

Sugi Predict / Compounds / Pacritinib

Pacritinib

Pacritinib

SCHEMBL1108221

C1=C/COCc2cc(ccc2OCCN2CCCC2)Nc2nccc(n2)-c2cccc(c2)COC/1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ACVR1FLT3IRAK1JAK2

The experimentally established mechanism targets of Pacritinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ JAK2 known ✓ O60674 20/20 1.00
▸ FLT3 known ✓ P36888 19/20 1.00
▸ IRAK1 known ✓ P51617 1/20 1.00
▸ ACVR1 known ✓ Q04771 1/20 1.00
▸ TYK2 P29597 17/20 1.00
▸ JAK1 P23458 14/20 1.00
▸ JAK3 P52333 13/20 1.00
▸ CDK2 P24941 12/20 1.00
▸ CCNA2 P20248 11/20 1.00
▸ CCNA1 P78396 11/20 1.00
▸ CYP2D6 P10635 2/20 1.00
▸ GAK O14976 1/20 1.00
▸ STK16 O75716 1/20 1.00
▸ STK10 O94804 1/20 1.00
▸ MAP4K4 O95819 1/20 1.00
▸ PRKCB P05771 1/20 1.00
▸ LCK P06239 1/20 1.00
▸ CSF1R P07333 1/20 1.00
▸ PDGFRB P09619 1/20 1.00
▸ NQO2 P16083 1/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Pacritinib SCHEMBL30802892 1.00 JAK2 (1.00) JAK2FLT3TYK2JAK1JAK3
Pacritinib SCHEMBL29395340 1.00 JAK2 (1.00) JAK2FLT3TYK2JAK1JAK3
Pacritinib SCHEMBL26687652 1.00 JAK2 (1.00) JAK2FLT3TYK2JAK1JAK3
Pacritinib SCHEMBL31537559 1.00 JAK2 (1.00) JAK2FLT3TYK2JAK1JAK3
Pacritinib SCHEMBL2537450 0.99 JAK2 (0.98) JAK2FLT3TYK2JAK1JAK3
SCHEMBL1108252 0.96 JAK2 (0.92) JAK2FLT3TYK2JAK1JAK3
SCHEMBL20322432 0.94 JAK2 (0.89) JAK2FLT3TYK2JAK1JAK3
Pacritinib SCHEMBL2485104 0.94 JAK2 (0.89) JAK2FLT3TYK2JAK1JAK3
SCHEMBL22560648 0.94 JAK2 (0.88) JAK2FLT3TYK2JAK1JAK3
Pacritinib SCHEMBL30277987 0.91 JAK2 (0.83) JAK2FLT3TYK2JAK1JAK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 179 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9624242-B2 11-2(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt CTI BIOPHARMA CORP. (US) 2017-04-18 — — US claimed
US-20150322084-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT SOBI, INC. 2015-11-12 — — US claimed
US-8980873-B2 11-(2-pyrrolidin-1-yl-ethoxy)-14,19-dioxa-5,7,26-triaza-tetracyclo[19.3.1.1(2,6).1(8,12)]heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene citrate salt CTI BIOPHARMA CORP. (US) 2015-03-17 — — US claimed
EP-2376500-B1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT CTI BIOPHARMA CORP (US) 2015-02-25 — — EP claimed
US-20140377221-A1 BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) 2014-12-25 — — US claimed
EP-2806883-A1 BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION Dnatrix Inc. (US) 2014-12-03 — — EP claimed
WO-2013112942-A1 BIOMARKERS AND COMBINATION THERAPIES USING ONCOLYTIC VIRUS AND IMMUNOMODULATION DNA TRIX, INC. (US) 2013-08-01 — — WO claimed
US-20110294831-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT S*BIO PTE LTD. (SG) 2011-12-01 — — US claimed
US-20110263616-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT S*BIO PTE LTD. (SG) 2011-10-27 — — US claimed
EP-2376499-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT S*BIO Pte Ltd (SG) 2011-10-19 — — EP claimed
WO-2010068181-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6)1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27)J16,21,23-DECAENE CITRATE SALT S*BIO PTE LTD (SG) 2010-06-17 — — WO claimed
US-20260097028-A1 Methods of Treating Myeloproliferative Neoplasms KARTOS THERAPEUTICS INC (US) 2026-04-09 — — US disclosed
US-20250387383-A1 METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS KARTOS THERAPEUTICS, INC. (US) 2025-12-25 — — US disclosed
US-12351571-B2 Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases ARRAY BIOPHARMA INC. (US) 2025-07-08 — — US disclosed
US-12268681-B2 Methods of treating myeloproliferative neoplasms KARTOS THERAPEUTICS, INC. (US) 2025-04-08 — — US disclosed
WO-2010068182-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT S*BIO PTE LTD (SG) 2010-06-17 — — WO disclosed
WO-2010068182-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT S*BIO PTE LTD (SG) 2010-06-17 — — WO disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD. (SG) 2009-03-19 — — US disclosed
WO-2007058627-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES S*BIO PTE LTD (SG) 2007-05-24 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250387383-A1 METHODS OF TREATING MYELOPROLIFERATIVE NEOPLASMS JAK2, JAK1, MPL JAK2 1/4885FLT3 22/4885IRAK1 331/4885
US-12268681-B2 Methods of treating myeloproliferative neoplasms JAK2, JAK1, PDPK1 JAK2 1/4885FLT3 78/4885IRAK1 256/4885
US-20090075999-A1 OXYGEN LINKED PYRIMIDINE DERIVATIVES DPYD, TK2, TK1 JAK2 468/4885FLT3 645/4885IRAK1 1610/4885
US-20260097028-A1 Methods of Treating Myeloproliferative Neoplasms JAK2, TP53, CDKN1A JAK2 1/4885FLT3 171/4885IRAK1 712/4885
US-20110294831-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT SLC10A1, IL17A, SLC25A1 JAK2 586/4885FLT3 1851/4885IRAK1 2203/4885
US-20150322084-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE CITRATE SALT SLC10A1, IL17A, SLC25A1 JAK2 586/4885FLT3 1851/4885IRAK1 2203/4885
US-20110263616-A1 11-(2-PYRROLIDIN-1-YL-ETHOXY)-14,19-DIOXA-5,7,26-TRIAZA-TETRACYCLO[19.3.1.1(2,6).1(8,12)]HEPTACOSA-1(25),2(26),3,5,8,10,12(27),16,21,23-DECAENE MALEATE SALT IL17A, SLC10A1, PKD1 JAK2 505/4885FLT3 3153/4885IRAK1 1923/4885
US-12351571-B2 Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases FGFR3, FGFR4, FGFR1 JAK2 39/4885FLT3 89/4885IRAK1 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.